drugset / Trial / NCT06539637

Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%

NCT06539637

Phase 0 Recruiting 20 enrolled DHS Consulting
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a clinical trial evaluating Ketorolac levels in vitreous and aqueous humor samples from patients undergoing combined cataract and pars plana vitrectomy surgeries with and without intracameral phenylephrine 1.0% / ketorolac 0.3% (OMIDRIA). Patients not receiving intracameral OMIDRIA will receive topical ketorolac prior to cataract surgery/pars plana vitrectomy.

Timeline

Start
2023-09-01
Primary completion
2025-11
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Other / unclassified 0.3 % Other
Subject Ketorolac Other / unclassified 0.5 % Other
Subject Ketorolac Other / unclassified 2.88 mg/ml Other
Subject Phenylephrine Small molecule 1 % Other
Subject Phenylephrine Small molecule 10.16 mg/ml Other

Indications